Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4044324 | 0.96 | CTSK (0.43) | CTSKCTSLCTSSHSD17B10HCRTR2 | |
| SCHEMBL4043172 | 0.95 | CTSK (0.41) | CTSKCTSLCTSSHSD17B10HCRTR2 | |
| SCHEMBL4040095 | 0.93 | CTSK (0.42) | CTSKCTSLCTSSHSD17B10HCRTR2 | |
| SCHEMBL4037702 | 0.91 | CTSK (0.43) | CTSKCTSLCTSSHSD17B10HCRTR2 | |
| SCHEMBL4040439 | 0.89 | CTSK (0.43) | CTSKCTSLCTSSCTSB | |
| SCHEMBL4042098 | 0.88 | CTSK (0.44) | CTSKCTSLCTSSF2F10 | |
| SCHEMBL4041053 | 0.88 | CTSK (0.44) | CTSKCTSLCTSSTSHRCYP11B1 | |
| SCHEMBL4042001 | 0.87 | CTSK (0.41) | CTSKCTSLCTSSCYP11B1CTSB | |
| SCHEMBL4043982 | 0.86 | CTSK (0.41) | CTSKCTSLCTSSKMT2ACYP11B1 | |
| SCHEMBL4041367 | 0.86 | CTSK (0.41) | CTSKCTSLCTSSCYP11B1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| WO-2009097312-A1 | CATALYTIC CONVERSION OF ETHANOL AND HYDROGEN TO A 1-BUTANOL-CONTAINING REACTION PRODUCT USING A THERMALLY DECOMPOSED HYDROTALCITE/METAL CARBONATE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009097310-A1 | CATALYTIC CONVERSION OF ETHANOL AND HYDROGEN TO A 1-BUTANOL-CONTAINING REACTION PRODUCT USING A THERMALLY DECOMPOSED HYDROTALCITE CONTAINING THE ANION OF ETHYLENEDIAMINETETRAACETIC ACID | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-08-06 | — | — | WO | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2009026523-A1 | CATALYTIC CONVERSION OF ETHANOL TO A 1-BUTANOL-CONTAINING REACTION PRODUCT USING A THERMALLY DECOMPOSED HYDROTALCITE/METAL CARBONATE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026510-A1 | CATALYTIC CONVERSION OF ETHANOL TO A 1-BUTANOL-CONTAINING REACTION PRODUCT USING A THERMALLY DECOMPOSED HYDROTALCITE CATALYST | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026483-A1 | CATALYTIC CONVERSION OF ETHANOL TO A 1-BUTANOL-CONTAINING REACTION PRODUCT USING A THERMALLY DECOMPOSED HYDROTALCITE CONTAINING THE ANION OF ETHYLENEDIAMINETETRAACETIC ACID | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSL 57/4885CTSS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.